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Abstract : The National Institute for Health and Clinical Excellence (NICE)
provides guidance to the National Health Service (NHS) in England and Wales
on funding and use of new technologies. This study examined the impact of
evidence, process and context factors on NICE decisions in 2004–2009. A data
set of NICE decisions pertaining to pharmaceutical technologies was created,
including 32 variables extracted from published information. A three-category
outcome variable was used, defined as the decision to ‘recommend’, ‘restrict’
or ‘not recommend’ a technology. With multinomial logistic regression, the
relative contribution of explanatory variables on NICE decisions was assessed.
A total of 65 technology appraisals (118 technologies) were analysed. Of the
technologies, 27% were recommended, 58% were restricted and 14% were
not recommended by NICE for NHS funding. The multinomial model showed
significant associations (p< 0.10) between NICE outcome and four variables:
(i) demonstration of statistical superiority of the primary endpoint in clinical
trials by the appraised technology; (ii) the incremental cost-effectiveness
ratio (ICER); (iii) the number of pharmaceuticals appraised within the
same appraisal; and (iv) the appraisal year. Results confirm the value of a
comprehensive and multivariate approach to understanding NICE decision
making. New factors affecting NICE decision making were identified,
including the effect of clinical superiority, and the effect of process and
socio-economic factors.
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Introduction
Health Technology Assessment (HTA) decisions represent a key point within
the complex decision making process that governs funding and access for pharma-
ceuticals in many health care systems. HTA decisions are of interest because of
their implications for patients, health care providers, funding bodies, technology
manufacturers and health policy makers. Successful implementation of HTA
requires multi-disciplinary assessment of the range of social, economic, clinical and
health care system organisational consequences stemming from the introduction of
a new technology relative to the existing standards of care (Henshall et al., 1997;
Velasco Garrido and Busse, 2005; HTAI, 2007; EUnetHTA, 2011). Therefore, it is
important to understand what factors are in fact driving HTA decisions.
Established in 1999, the National Institute for Health and Clinical Excellence
(NICE) is responsible for providing guidance to the National Health Service
(NHS) in England and Wales on the funding of new technologies and their use
(Chalkidou, 2009). There are four types of guidance that NICE provides
including: clinical guidelines, public health guidelines, guidelines on safety and
efficacy of interventional procedures and recommendations on ‘health technologies’
(such as surgical interventions and pharmaceuticals; NICE, 2008b). One of the
key rationales for setting up NICE was to help tackle the geographic inequality
in access to technology or the phenomenon more frequently referred to as
‘postcode prescribing’ (Summerhayes and Catchpole, 2006). Since 2002, NICE’s
recommendations have been mandatory and NHS organisations have had to
comply, usually within three months.1
Within NICE, the Centre for Health Technology Evaluation focuses on issuing
guidance on the appropriate use and funding of technologies. The NICE HTA
process involves a panel of clinical, academic and industry stakeholders and the
general public (NICE, 2008a). Appraisals by NICE are governed by the use of
established standard methodology for the evaluation of clinical and economic
characteristics of the technology (NICE, 2008a; Littlejohns et al., 2009). As
outlined in its methods guide (NICE, 2008a), a range of clinical criteria are
evaluated during a NICE appraisal and the submission of cost-utility evidence is
an integral part of the process. In addition to economic and clinical criteria, the
patients’ perspective and patient evidence, as well as the perspective of carers and
other members of the NHS, are taken into consideration via the consultation and
stakeholder submission processes. NICE operates a process that emphasises the
roles of social values in decision making (Littlejohns et al., 2009), especially
during appraisal of clinical effectiveness and cost-effectiveness evidence (NICE,
2008b). Social value principles considered by NICE include a focus on promoting
equality and key ethical principles in decision making, including the notion of
‘procedural justice’, a principle through which NICE is committed to ‘‘ensuring
1 However, the new Conservative–Liberal Democrat government elected in May 2010 have indicated
that they will change NICE’s role and its coverage recommendations may only have advisory status.
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that the processes by which healthcare decisions are reached are transparent, and
that the reasons for the decisions are explicit’’ (NICE, 2008b, p. 12).
Given the multidimensional nature of NICE decision making and the high degree
of stakeholder involvement, it is hypothesised that decisions are influenced not only by
the evidence supporting the technology, but also by the assessment processes used and
the context in which they operate. The overall objective was to examine the impact of
evidence, process and context factors on decisions made by NICE to recommend,
restrict or not recommend new technologies for use in England and Wales.
Method
Hypothesised drivers of HTA decision making
It was hypothesised, based on the literature available, that HTA decisions were
driven by the HTA decision-making process, the evidence considered within that
process and by the socio-economic and political context in which those decisions
were made (Figure 1). Research on the impact of evidence on the HTA decision
has shown that the evidence related to the medicine or other technology under
review (whether clinical, economic or otherwise) can influence HTA decisions
[see for example, (Devlin and Parkin, 2004; Dakin et al., 2006; Clement et al.,
2009; Mason and Drummond, 2009)]. For instance, previous studies of NICE
decision making have highlighted the significant impact of clinical evidence as
well as the incremental cost-effectiveness ratio (ICER) (Devlin and Parkin, 2004;
Dakin et al., 2006). The literature has also raised questions about the degree to
which NICE decisions may be influenced by the nature of the disease for which
the technology is indicated. There has been particular focus on cancer therapies
and the degree to which there may be flexibility in the criteria used to appraise
technologies, given the severity of the disease and clinical needs. A review of
NICE appraisals related to cancer technologies suggested that there was an
increase in non-recommendation over time, although not statistically significant
Figure 1. HTA decision making: hypothesised drivers. HTA5 health technology assessment
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(Mason and Drummond, 2009). In contrast, NICE has also been characterised
as being more flexible in its application of a cost-effectiveness threshold to
cancer therapies (NICE, 2009). This presents an opportunity within this analysis
to further investigate as to what extent disease characteristics influence NICE
decision making, when taking into account other confounding factors.
The literature examining the HTA appraisal process provided insights into
a number of process-related factors that can potentially influence HTA decisions
(e.g. Al et al., 2004; Menon et al., 2005; OECD, 2005; Vuorenkoski et al., 2008).
Within NICE decision making, the use of multiple technology appraisals (MTA) or
single technology appraisals (STA) process has been hypothesised to affect decision
making (Barbieri et al., 2009). MTA and STA are two appraisal processes used by
NICE to issue guidance on technologies. The MTA process includes a third-party
review and analysis of the clinical and economic evidence, whereas the STA process
relies on manufacturer-provided information (Barbieri et al., 2009). However, the
lack of an adequate sample size and the use of descriptive rather than multivariate
analyses impeded the authors from examining the role of appraisal process on
NICE decisions. Therefore, it was identified as an area of interest for this analysis.
Finally, reference in the literature was made to the impact of the overall health care
and welfare characteristics on HTA decision making, such as health care spending
per capita, societal willingness to pay, the structure of the health care system, as
well as ethical and social considerations (e.g. Ross, 1995; Owens, 1998; Buxton,
2005; Packer et al., 2006; Bryan et al., 2007). In their model of NICE decision
making between 2000 and 2003, Dakin et al., (2006) found a statistically signi-
ficant effect of the time of appraisal on outcome; therefore, it was of interest to
establish whether this effect was observed in later appraisals.
Thus, based on the analytical model, the hypotheses tested in this analysis of
NICE decision making were:
> Whether the ICER significantly affects NICE decision making; specifically,
whether an increase in the ICER decreases the odds of recommendation.
> Whether technologies for cancer therapies increase the odds of recommenda-
tion relative to non-recommendation.
> Whether the use of an MTA process increases the odds of restriction relative to
recommendation, compared with the STA process.
> Whether non-recommendations and restrictions are increasing over time
relative to recommendations.
In testing these hypotheses, the study also sought to make comparisons with
previously published models of NICE decision making (Devlin and Parkin,
2004; Dakin et al., 2006).
Sample
The pharmaceutical technology appraisals performed by NICE formed the basis for
the sample included in this analysis. The composition of the sample was determined
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through the following inclusion and exclusion criteria. The sample included all
pharmaceutical technology appraisals (as opposed to medical devices or other
interventions) performed during the period 2004–2009, indicated for an adult
population. A five-year time horizon was used to capture a sufficient number of
appraisals for analysis. Technology appraisals were excluded from the analysis for
any of the following reasons: (i) they focused on a non-adult population (aged ,18
years); (ii) the appraised technologies were non-pharmaceutical interventions; (iii)
marketing authorisation was withdrawn; or (iv) the full guidance was not available.
Outcome variable
The analysis was designed to reflect as closely as possible the way NICE makes
its decisions. To this end, a three-category outcome variable was used where
technologies were recommended, restricted or not recommended. A three-
category outcome variable was preferred over a binary outcome variable
(i.e. covered vs not covered), as it better reflected the multiple coverage options
available to NICE. Ranking of the three potential outcomes was not imple-
mented as ranking of outcomes can vary according to the perspective adopted.
NICE guidance (summarised in section 1 of each guidance) indicates whether an
intervention should be recommended or not for use in the NHS. A medication was
considered as not recommended for use by NICE guidance if the words ‘not
recommended’ were stated in section 1 of the guidance. To distinguish between
recommended and restricted interventions, decision rules were developed to help
classify which of the recommendations issued from NICE guidance were for routine
use, and those that were for restricted use. Specifically, the Raftery classification was
utilised to distinguish between restriction and recommendation (Raftery, 2006).
Where a recommendation was made for a technology to be used in a population
identical to its licensed indication, it was considered to be ‘recommended’. Where a
recommendation contained one of the following provisos in relation to the tech-
nology, it was considered to be ‘restricted’: (i) it should be used in a sub-population
of its licensed indication; (ii) it should be used in a second line or higher line of
therapy; (iii) it required monitoring; (iv) it should be used at the lowest acquisition
cost; or (v) it required prescription by a specialist (Raftery, 2006).
Explanatory variables
In line with the hypothesised drivers of HTA decision making, 32 variables were
defined, including those relating to (i) the clinical and economic characteristics
of the technology under appraisal [such as characteristics of randomised controlled
trials (RCTs), use of observational data, ICER reported], (ii) the processes used to
come to a decision (such as use of STA or MTA) and (iii) the socio-economic
context in which these decisions were made [including percentage Gross Domestic
Product (GDP) spent on health care, year of appraisal and if disease was identified
as a priority]. These are shown in Table 1.
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Table 1. NICE data set includes variables, definitions, data extraction rules and data sources
No. Variable Definition
1 NoRCT The number of distinct RCTs that provide data related to the therapeutic
indication under evaluation. Excluded: studies that are single arm, that have no
randomisation or that are non-interventional. (1)
2 RCTsize Mean number of patients per RCT. (1)
3 RCTduration Mean number of weeks that data are collected on patients who entered the RCTs
(see variable no. 1). (1)
4 RCTsignificant Presence of statistically significant superiority of technology vs comparator for
primary endpoint(s). If more than one RCT was considered, and the technology
showed statistically significant superiority in one trial, but not in another, the
results were considered to be ‘inconsistent’ and classified as such. RCTs designed
as ‘non-inferiority’ studies were classified as not showing any statistically
significant superiority (i.e. ‘no’). (1)
5 RCTcomparator Percentage of RCTs where an active comparator was used. (1)
6 ObsStudies Number of observational studies providing information to support the study
pharmaceutical. Observational studies in this circumstance are defined as studies
that are non-interventional (i.e. do not explicitly request the patient to take
particular medication or the physician to follow a particular protocol). (1)
7 Priority This variable aims to capture the health policy context in which the decision is
made by capturing whether the pharmaceutical in question is linked to a disease
area that is prioritised by the Department of Health. Priority disease areas were
identified by examining government plans/health documents that highlight
national health care system focus. (2)
8 OrphanDesig This variable captured information on whether or not the technology was
recognised by the EMA as an orphan-designated medicine. (3)
9 Disease The BNF categories were used to classify each technology into the corresponding
therapeutic area. (4)
10 Eligiblepop Reported number of patients eligible for treatment, defined by patient population
for which the technology is indicated. (1, 3)
11 AlternativeTx Captures whether an alternative treatment option was available. An alternative
was considered to be available if comparators were clearly defined in the review
by the HTA agency. An alternative was considered NOT to be available if it was
stated as such in the appraisal, or if ‘best supportive care’ or ‘palliative care’ was
specified as the comparator. (1)
12 CUA Presence or absence of a cost-utility analysis. (1)
13 ICER ICER (Cost per QALY) reported in the HTA dossier for base–case as accepted by
the Appraisal Committee. This is defined as the ICER that is related to the
recommendation. If more than one ICER is presented due to the recommendation
covering more than one population, and then the ICER pertaining to the larger
of the populations was reported. In NICE appraisals, if no ICER was reported
by the Appraisal Committee, then the ICER reported by the Assessment Group
was used. The ICER reported in the manufacturer submission was used if it was
not stated in the guidance or the assessment group report. If the technology is
reported as dominant or dominated, it was recorded as such in the data extraction
sheet. (1)
14 MultipleCEA Whether more than one cost-utility or cost-effectiveness model was considered
during the appraisal. (1)
15 MultipleICERs If response to variable 14 is ‘yes’, report range of base–case ICERs presented
between the different models reported. The difference between the lowest and
highest ICER will be calculated. (1)
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Table 1. (Continued)
No. Variable Definition
16 ProbabilisticICER This should be reported as the percentage probability of acceptance at the
threshold used by the agency. The probability of medication to be cost-effective at
a 30,000 GBP threshold was reported. (1)
17 UnivariateICER This should be reported as the range of ICERs (min–max) resulting from
univariate sensitivity on the base–case. (1)
18 NonCUA Indicates whether non-cost per QALY economic analyses were submitted and
reviewed. (1)
19 BudgetImp Estimated annual incremental budgetary impact of introducing new medication
into the current treatment setting, if the pharmaceutical were to be introduced
without any restriction. Pharmaceutical cost only (per year). This is the potential
budget impact where a recommendation for use is the total indicated population
to be granted. (1)
20 PatientSub A patient submission was considered to have been included as part of the
appraisal process if a submission from a patient group was posted on the webpage
pertaining to the guidance. (5)
21 NoDecMakers Captures the number of decision makers accountable for guidance issued,
as reported. (1)
22 CEAprocess Captures whether cost-effectiveness is a component of the decision-making
process or not. If cost-effectiveness analysis is a formal part of the appraisal
process, this variable was marked as ‘yes’. (1, 6)
23 BudgetImpProcess Captures whether budget impact considerations are part of decision-making
process. (1, 6)
24 Price Captures whether the price of the technology under appraisal was known during
the assessment. (1)
25 MTAvsSTA Records whether guidance was issued after the appraisal of an individual
technology following the STA or MTA process. As the STA process was
introduced in 2006, those technologies appraised before this year were
automatically considered as having been appraised via an MTA. (1)
26 NoTech This variable captures the number of technologies appraised simultaneously in
the appraisal. (1)
27 Accountability The HTA agency was examined to assess whether the agency making the funding
decisions is also accountable for the pharmaceutical budget or not. (7)
28 Date Year when decision was issued. (1)
29 PopulationSize Estimate of population size within remit of the agency performing
the evaluation. (8)
30 HealthcareGDP Percentage of GDP spent on health care during year of decision. (9)
31 HealthExp Health care budget spent on pharmaceuticals per patient per year, during the same
year in which the appraisal was published. (10)
32 Election This variable captures whether the decision was made within an election year.
An election year was defined as a year in which either national government or
regional elections took place. (11)
RCT5Randomised Controlled Trials; EMA5European Medicines Agency; BNF5British National Formulary;
HTA5health technology assessment; CUA5 cost-utility analysis; ICER5 incremental cost-effectiveness ratio;
NICE5National Institute for Health and Clinical Excellence; MTA5multiple technology appraisals; GDP5
gross domestic product; STA5 single technology appraisals; TAR5Technical Appraisal Report.
(1) TAR, sections 3–4; (2) Department of Health (2002, 2006a, 2006b, 2007); (3) EMA (2011); (4) BNF,
Joint Formulary Committee (2010); (5) Section on NICE appraisal webpage (nice.org.uk) describing the
history of the appraisal; (6) NICE (2009); (7) Sorenson et al. (2008); (8) National Office for Statistics (2009);
(9) OECD (2006); (10) Association of the British Pharmaceutical Industry (ABPI) (2010); (11) BBC (2005).
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Data set
A database of information pertaining to NICE decisions and explanatory
variables of interest was developed. To create this database, several steps were
implemented. Publicly available sources of data containing information on the
variables of interest were identified, and a data extraction form was developed
to extract information from the different appraisals in a way that was as
transparent, reproducible and consistent as possible. Finally, the resulting
extracted data were coded and prepared for analysis. The variable definitions
and data sources used are shown in Table 1.
Statistical analyses
A multinomial logit regression was used in the analysis to model the prob-
abilities associated with the three types of technology appraisal outcomes
(recommended, restricted or not recommended). We selected the ‘recommended’
outcome as the referent category in the analysis.
The objective of the analysis was to identify, ceteris paribus, the effect of
a range of factors potentially associated with NICE appraisal decisions, and to
assess which combination of factors best explains the pattern of NICE decisions.
Given the wide range of factors considered in the analysis (see Table 1), a
process was developed to determine which explanatory variables would appear
in the final specification of the model. This process involved the following steps:
> First, bivariate regression models were run to ascertain the degree of
correlation between individual explanatory variables and appraisal decisions.
> On the basis of these models, a subset of indicators was selected, which
included those variables that showed at least moderate significance levels
(indicators with a p-value below 0.25). A preliminary model was estimated
including these indicators.
> The model was reduced by removing those variables with significance levels
above the 0.10 threshold. To guarantee its stability, this ‘base’ model was
re-estimated by sequentially removing one variable at a time and verifying the
stability of the effects on the coefficient and significance level of the remaining
estimates.
> The model was subsequently tested through alternative model specifications to
examine its robustness and to assess the sensitivity of the results to different
assumptions.
> As a final step, the base–case model results were presented to the
representatives of NICE to seek feedback on the variables identified within
the base–case model, the coefficient and level of significance to assess the
validity of the model.
The application of the model-specification process outlined above facilitated
the interpretation of the results of the models, while allowing the analysis to
explore the impact of the wide range of indicators collected in the study.
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Although significant effort was made to identify the information relevant to the
variables of interest, a limited proportion of data could not be found and was
therefore missing (see Table 2). To maximise the sample size, imputation techniques
were used to estimate entries for missing values. Missing values were replaced with
regression imputation estimates using the ‘impute’ command in STATA software
[Intercooled (IC) Stata version 10.1]. The imputed values obtained were then checked
manually to ensure their face validity. In addition, dummy variables were created to
identify observations with missing data to test in the regression models whether the
lack of data was significantly associated with differences in the outcome variable.
A series of sensitivity analyses were performed on the base–case regression
model to help evaluate the robustness of the results. The sensitivity analyses
included: (i) examining the impact of a binary rather than a three-category
outcome variable; (ii) restricting the base–case analysis to complete observa-
tions, thus excluding observations with imputed values; and (iii) estimating the
model assuming ordinal properties of the outcome variable.
Descriptive statistics were calculated for each extracted variable, stratified by
outcome group (recommended, restricted or not recommended). For categorical
variables, the x2-test was conducted across the three outcomes, at a 0.05 sig-
nificance level. With regard to non-categorical variables, analysis of variance
and Kruskal–Wallis tests were carried out, at a level of significance of 0.05.
Statistical analyses were performed using IC Stata (version 10.1 2009).
Results
Of 99 NICE technology appraisals, 65 were included in the analysis, repre-
senting 118 technologies. A total of 34 technology appraisals were excluded
from the analysis for the following reasons: (i) they focused on a non-adult
population (n55); (ii) they appraised non-pharmaceutical interventions (n523);
(iii) marketing authorisation was withdrawn (n5 2); or (iv) full guidance was
not available (n54). The majority of decisions restricted funding for the
appraised technology (58%), 27% were recommended, whereas the least
common decision was non-recommendation (14% of technologies).
Table 2. Description of missing data within NICE data set 2004–2009
Proportion of incomplete entries (%) 8%
Missing entries by outcome variable Recommended: 5%
Restricted: 9%
Not recommended: 9%
List variables with missing values (top three variables) Univariate uncertainty estimates around ICER
Probabilistic sensitivity analysis
Missing entries per appraisal (mean and range) 3 (range: 0–9)
NICE5National Institute for Health and Clinical Excellence; ICER5 incremental cost-effectiveness ratio.
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Univariate analysis
Of the 32 explanatory variables examined, descriptive analysis suggested that a
subset of 20 variables may play an important role in determining NICE decision
making (Table 3). Six variables related to the clinical evidence supporting the
technology under evaluation. The first three variables described the nature of the
randomised clinical trial data available in terms of the number of trials, sample
size and trial duration. Interventions recommended for use or for restricted use
were supported by a higher number of RCTs (mean of seven and eight trials,
respectively), compared with interventions not recommended for use (mean
three trials, p, 0.05). The mean size of the patient sample included in RCTs was
higher for those interventions recommended by NICE (mean5 1765 patients),
compared with those interventions restricted or not recommended by NICE
(1044 and 1154 patients, respectively, p,0.05). The mean trial duration
across the three outcome groups was 96, 66 and 82 weeks, respectively (ns). Of
the recommended interventions, 59% demonstrated statistically significant
superiority, as opposed to 29% of restricted and 35% of not recommended
interventions (p,0.05). Recommended interventions were more likely to have
active comparators within the RCTs (63%) than interventions that were
restricted or not recommended (40%, 44% of RCTs with active comparators,
respectively, p,0.05). Very little observational data were referred to in NICE
appraisals (the mean across appraisals was 0.6 observational studies, not
significant across outcomes).
The effect of economic evidence on NICE decision was significant. The
majority of NICE decisions were backed by cost-utility evidence (95%). In 65%
of decisions, multiple economic models were considered in the appraisal process
and the use of multiple models was consistent across outcome categories. For
the interventions supported by a cost-utility analysis, the ICER was significantly
different (p,0.001) between the recommended interventions (mean ICER of
£17,782), compared with the restricted interventions (mean ICER of £24,867)
and the interventions not recommended for use (mean ICER of £99,239). The
probability of the ICER remaining below £30,000 was 61% for recommended
interventions, 41% for restricted interventions and 8% for interventions not
recommended for use (p,0.01). With regard to univariate sensitivity analyses, the
range of uncertainty was smallest for those interventions that were restricted for use
(£19,747–£ 57,146), the widest range of uncertainty was observed for interventions
not recommended for use (£92,379–£731,151; p,0.05). Although the ICER is an
important variable in NICE decision making, there are exceptions to its usefulness
as a predictor of HTA decisions – there are recommended technologies with
very high base–case ICERs, as there are technologies with lower base–case ICERs
that are not recommended (Figure 2). This suggests the importance of examining
a combination of factors to explain NICE decision making.
The effect of the appraisal process was found to be significant. On average, 25%
of decisions followed the STA process – and this varied across outcomes: 41% of
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Table 3. NICE decisions 2004–2009: mean values for explanatory factors, stratified by decision (lower, upper 95% CI)
Total (n5 118)
Recommended
(n5 32) Restricted (n5 69)
Not Recommended
(n5 17) p-value
NoRCT 6.7 (5.2, 8.3) 6.8 (2.1, 11.4) 7.6 (5.9, 9.2) 3.4 (2.1, 4.8) ,0.05 3
RCTsize 1249 (807, 1691) 1765 (804, 2727) 1044 (442, 1645) 1154 (464, 1844) ,0.05 3
RCTduration 76.2 (63.5, 88.9) 95.9 (65.9, 125.8) 65.8 (51.5, 80.2) 81.9 (41.5, 122.3) ns 1
RCTsignificant
Yes 38% (29%, 47%) 59% (41%, 77%) 29% (18%, 40%) 35% (10%, 61%) ,0.05 2
No 15% (9%, 22%) 6% (23%, 15%) 17% (8%, 27%) 24% (1%, 46%) ns 2
Inconsistent 43% (34%, 52%) 31% (14%, 48%) 51% (39%, 63%) 35% (10%, 61%) ns 2
RCTcomparator 47% (39%, 55%) 63% (46%, 80%) 40% (30%, 50%) 44% (18%, 69%) ,0.10 3
ObsStudies 0.6 (0.1, 1.1) 1.5 (20.4, 3.4) 0.3 (0.1, 0.5) 0 (0,0) ns 1
CUA 95% (91%, 99%) 100% (100%, 100%) 94% (89%, 100%) 88% (71%, 105%) ns 2
ICER £31,910 (£20,945,
£42,874)
£17,782 (£11,066,
£24,498)
£24,867 (£21,002,
£28,731)
£99,239 (£11,882,
£186,597)
,0.01 3
MultipleCEA 65% (56%, 74%) 69% (52%, 86%) 63% (51%, 75%) 67% (40%, 94%) ns 2
MultipleICERs – low range £13,318 (£10,511,
£16,125)
£8607 (£4,551,
£12,664)
£13,417 (£10,119,
£16,714)
£21,441 (£9,663,
£33,220)
,0.01 3
MultipleICERs – high range £107,421 (£66,886,
£147,956)
£83,666 (2£12,619,
£179,951)
£129,690 (£85,202,
£174,179)
£83,242 (£33,511,
£132,974)
,0.01 3
Univariate ICER – low value £25,417 (£6,412,
£44,422)
£7,881 (£5,234,
£10,527)
£19,747 (£4,460,
£35,035)
£92,379 (2£58,911,
£243,668)
,0.01 1
UnivariateICER –high value £167,389 (£56,865,
£277,913)
£113,286 (£1293,
£225,279)
£57,146 (£29,962,
£84,329)
£731,151 (2£83,313,
£1,545,615)
,0.05 3
ProbabilisticICER 43% (34%, 52%) 61% (45%, 77%) 41% (29%, 53%) 8% (21%, 17%) ,0.01 3
NonCUA 22% (14%, 30%) 22% (7%, 37%) 28% (17%, 38%) 0% (0%, 0%) ,0.10 2
BudgetImp (million) £708 (£182, £1235) £36 (£18, £54) £828 (£51, £1606) £1,632 (2£610, £3874) ,0.10 3
Eligiblepop 2,288,409 (1,189,422,
3,387,396)
392,063 (82,017,
702,109)
3,194,243 (1,419,388,
4,969,097)
2,270,955 (2290,109,
4,832,019)
,0.01 3
AlternativeTx 89% (83%, 95%) 88% (75%, 100%) 90% (83%, 97%) 88% (71%, 105%) ns 2
PatientSub 87% (81%, 93%) 91% (80%, 101%) 84% (75%, 93%) 94% (82%, 107%) ns 2
NoDecMakers 30 (28, 32) 28 (25, 31) 31 (29, 34) 28 (23, 33) ns 1
CEAprocess 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) n/a n/a
BudgetImpProcess 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) n/a n/a
Price 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%) n/a n/a
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Table 3. (Continued)
Total (n5 118)
Recommended
(n5 32) Restricted (n5 69)
Not Recommended
(n5 17) p-value
MTAvsSTA 25% (17%, 32%) 34% (17%, 52%) 16% (7%, 25%) 41% (15%, 67%) ,0.05 2
NoTech 2.8 (2.5, 3.2) 2.0 (1.5, 2.5) 3.4 (2.9, 3.9) 2.1 (1.5, 2.7) ,0.01 3
Accountability 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) n/a n/a
Date 2007 (2006, 2007) 2006 (2006, 2007) 2007 (2006, 2007) 2007 (2007, 2008) ,0.05 1
PopulationSize (million) 53.90 (53.80, 54.00) 53.8 (53.7, 54) 53.9 (53.8, 54.1) 54.2 (54, 54.4) ,0.05 1
HealthcareGDP 8% (8%, 8%) 8% (8%, 8%) 8% (8%, 8%) 8% (8%, 8%) ,0.05 3
HealthExp £175 (£173, £176) £173 (£171, £175) £174 (£173, £176) £178 (£175, £180) ,0.05 1
Election 7% (2%, 11%) 6% (23%, 15%) 7% (1%, 14%) 6% (27%, 18%) ns 2
Priority 56% (47%, 65%) 59% (41%, 77%) 57% (45%, 69%) 47% (21%, 74%) ns 2
OrphanDesig 3% (0%, 5%) 3% (23%, 9%) 3% (21%, 7%) 0% (0%, 0%) ns 2
Disease
Cardiovascular system 10% (5%, 16%) 13% (0%, 25%) 12% (4%, 19%) 0% (0%, 0%) ns 2
Central nervous system 15% (9%, 22%) 6% (23%, 15%) 22% (12%, 32%) 6% (27%, 18%) ,0.10 2
Ear, nose and oropharynx 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) ns 2
Endocrine system 1% (21%, 3%) 0% (0%, 0%) 1% (21%, 4%) 0% (0%, 0%) ns 2
Eye 2% (21%, 4%) 3% (23%, 9%) 0% (0%, 0%) 6% (27%, 18%) ns 2
Gastro-intestinal system 2% (21%, 4%) 0% (0%, 0%) 1% (21%, 4%) 6% (27%, 18%) ns 2
Infections 12% (6%, 18%) 19% (4%, 33%) 7% (1%, 14%) 18% (23%, 38%) ns 2
Malignant disease and
immunosuppression
31% (22%, 39%) 41% (23%, 59%) 23% (13%, 33%) 41% (15%, 67%) ns 2
Musculoskeletal and joint
diseases
19% (12%, 27%) 16% (2%, 29%) 22% (12%, 32%) 18% (23%, 38%) ns 2
Nutrition and blood 3% (0%, 5%) 0% (0%, 0%) 4% (21%, 9%) 0% (0%, 0%) ns 2
Obstetrics/gynaecology, &
urinary-tract disorders
0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) 0% (0%, 0%) ns 2
Respiratory system 1% (21%, 3%) 0% (0%, 0%) 1% (21%, 4%) 0% (0%, 0%) ns 2
Skin 5% (1%, 9%) 3% (23%, 9%) 6% (0%, 11%) 6% (27%, 18%) ns 2
Test 1. Both ANOVA and Kruskal–Wallis test indicate similar level of statistical significance; Test 2. x2-test used as categorical variable; Test 3. Either ANOVA or Krus-
kal–Wallis test indicates statistical significance.
ns5 not significant; n/a5 not applicable.
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interventions that were not recommended for NHS funding followed the STA
process, as opposed to 16% of restricted interventions and 34% of recommended
interventions (p50.031). The number of technologies reviewed per appraisal
was also statistically significantly different between outcome groups: restricted
interventions were simultaneously appraised together with an average of 3.4
technologies compared with recommended and not recommended interventions
(two technologies appraised simultaneously on average).
A range of socio-economic context variables varied significantly across NICE
decision categories, including the year of appraisal, population size, health
care expenditure as percentage of GDP and average health care expenditure per
patient per year.
Multivariate analysis
The multinomial model showed significant associations (p50.10) between NICE
outcome and four variables: (i) whether statistical superiority of the primary
endpoint in the clinical trial was demonstrated by the appraised technology,
(ii) the ICER, (iii) the number of pharmaceuticals appraised within the same
appraisal and (iv) the year of the appraisal (Table 4). Specifically, demonstration
by the technology under appraisal of statistically significant superior efficacy
decreased the log odds of a restriction or non-recommendation (p50.006 and
p50.016). A unit increase in the ICER increased the log odds of moving from
a recommended to a restricted decision (p50.009) vs recommendation and
a not recommended decision vs recommendation (p,0.001). The number of
technologies reviewed simultaneously within the same appraisal had a statistically
significant impact on the decision between recommendation and restriction
(p,0.05) but not between recommendation and non-recommendation (ns).
GBP 0
GBP 50,000
GBP 100,000
GBP 150,000
GBP 200,000
GBP 250,000
NICE Appraisals 2004-2009  reporting an ICER, ranked by ICER
Recommended Restricted Not Recommended
Figure 2. Base-case ICER(GBP) reported in NICE appraisals, by decision category (n5 90)
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For every additional year, this increased the odds of a restriction (vs recommen-
dation; p50.072) and the odds of a non-recommendation (vs recommendation;
p50.028). When NICE decisions were regressed with these four variables, the
resulting pseudo-R2 was 0.26, suggesting that the four variables explained ,26%
of the variability in NICE decisions.
Sensitivity analyses
A series of sensitivity analyses were performed on the base–case regression
model to help evaluate the robustness of the results. The first sensitivity analysis
assessed whether the impact of the explanatory variables on decision making
varied if a binary outcome variable was utilised instead of the base–case three-
category outcome variable. The logistic regression results using a binary
outcome variable (covered vs not covered) no longer showed a predictive value
for demonstration of clinical superiority (p50.657). However, in other aspects,
the results are similar to the base–case analysis in that they confirm the impact of
the ICER, number of pharmaceuticals appraised and the year of appraisal on
NICE decisions.
In the second sensitivity analysis, the regression analysis was run for a subset
of complete observations (n598/118). This sensitivity analysis was imple-
mented with the knowledge that removing incomplete observations from
the analysis could bias the analysis. The pseudo-R2 for this model was 0.32,
Table 4. Multivariate analysis of NICE decisions 2004–2009: base–case model results (n5118)
Log odds p-value 95% CI
Restricted
Clinical superiority demonstrated in RCT 21.568 0.006 22.679 20.457
ICER 0.000048 0.009 0.000012 0.000085
Number of technologies appraised
simultaneously
0.489 0.005 0.144 0.834
Year of appraisal 0.358 0.072 20.032 0.748
Constant 2718.973 0.071 21500.761 62.815
Not recommended
Clinical superiority demonstrated in RCT 22.01 0.02 23.64 20.38
ICER 0.000087 ,0.001 0.000042 0.000131
Number of technologies appraised
simultaneously
0.12 0.65 20.39 0.63
Year of appraisal 0.67 0.03 0.07 1.27
Constant 21351.14 0.03 22552.90 2149.38
NICE5National Institute for Health and Clinical Excellence; CI5 confidence interval; RCT5
Randomised Controlled Trials; ICER5 incremental cost-effectiveness ratio.
Recommended technologies are the reference case.
Multinomial logistic regression, pseudo-R2: 0.26.
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suggesting that this set of variables explains ,32% of the variability observed
in NICE decision making, as opposed to 26% in the base–case model.
In this sensitivity analysis, the impact of the ICER and the year of appraisal
remained similar to that observed in the base–case analysis: however, the
impact of the demonstration of statistical superiority, as well as the number of
technologies appraised simultaneously, was weaker in this sensitivity analysis
as a statistically significant effect on the odds of non-recommendation was no
longer observed.
In the third sensitivity analysis, ordinality of the outcome variable was
assumed and ordinal logistic regression was used. The results of this analysis
show very similar results to the base–case analyses.
Discussion
This study aimed to contribute to the literature on NICE decision making in
several ways. First, it examined NICE decision making beyond its initial years:
published multivariate analyses of NICE decision making have relied on data
from 2000 to 2003, during the years following NICE’s inception (e.g. Dakin
et al., 2006). The results of this new analysis provide a complementary view on
the characteristics of technologies reviewed by NICE beyond 2003, the factors
that have continued to have an impact on NICE decision making and oppor-
tunity to examine change in NICE decision making outcomes over time. Second,
this study aimed to complement extant studies of NICE decision making by
considering new variables not previously examined. The value of this approach
was twofold: it allows for the examination of impact of new variables on
NICE decision making (e.g. impact of therapeutic indication or use of STA vs
MTA processes); and it allows for the control of confounding factors in the
multivariate analysis.
Finally, by increasing the number of appraisals included in the analysis, this
study has greater statistical power when examining factors potentially having an
impact on NICE decision making. For example, Dakin et al. (2006) reported
that regression analysis including cost per QALY data was not feasible because
of the relatively small sample size. Therefore, the impact of the cost-effectiveness
ratio was assessed combining both cost per QALY and cost per life year cost-
effectiveness ratios and was not found to have a statistically significant impact
on the regression analysis.
This study of NICE decisions suggests that a combination of clinical,
economic and process factors explains decisions made by NICE to recommend,
restrict or not recommend pharmaceutical technologies for use. The internal
validity of the results obtained in this analysis was examined in two ways: first,
by comparing the results with published analyses of NICE decision making,
and second, by sharing the base–case model results for review with a leading
member of NICE.
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Pattern of NICE decision making
The pattern of NICE decisions observed in this analysis is not dissimilar to that
reported in a study by Kanavos et al. (2010), which examined NICE decisions in
2007–2009: that analysis revealed that, of the technologies appraised, 19%
were recommended, 63% were restricted and 18% were not recommended.
Clement et al. (2009) examined NICE decisions between 2001 and 2008 and
reported 87% of technologies as listed (recommended or restricted), leaving
13% of technologies as not recommended. Analysis of NICE decision making
during the year 2000–2003 by Dakin et al. (2006) reported that 21% of tech-
nologies were recommended for routine use, 66% were for restricted use and
13% were not recommended. Devlin and Parkin (2004) examined NICE out-
comes using a binary outcome variable, and during the period 2000–2002 found
that 71% of appraisals recommended use of the technology and 29% of
appraisals did not. Therefore, the pattern observed within the data set used in
this new study seems similar to that observed in previous studies, suggesting that
the method of classification and data extraction used was robust.
Impact of clinical evidence and disease characteristics on NICE
decision making
It was hypothesised that clinical variables, which were found to be significant
explanatory variables in previous NICE analyses, would maintain their sig-
nificance in this analysis. In the analysis of NICE decision making presented
here, demonstration by the technology under appraisal of statistically significant
superiority in its primary endpoint increased the odds of recommendation.
Technologies recommended by NICE demonstrated statistically significant
superior efficacy over the comparator in 59% of appraisals, compared with
29–35% of technologies that were restricted or not recommended. This result
can be seen to reflect the role of evidence-based medicine in HTA decisions and
the fact that NICE defines the value of the compound in terms of the ability of
the technology to demonstrate, with greater certainty, its incremental clinical
value through superiority-designed trials that provide stronger data to support a
funding decision than technologies not able to provide evidence of superior
efficacy. Comparing this result with previous studies, it is noteworthy that
Devlin and Parkin (2004) did not measure the demonstration of clinical
superiority, whereas Dakin et al. (2006) measured this variable but did not find
it to have a statistically significant impact, although the sample size was smaller
than that used here, and their study examined appraisals made in 2000–2003.
It was hypothesised that technologies for diseases characterised by high unmet
medical need may increase the log odds of recommendation relative to non-
recommendation – with particular focus on cancer therapies. Through the
model-specification process, the effect of cancer therapies on the log odds of
non-recommendation was not observed and thus the final base–case model does
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not include this particular variable. The hypothesis was also not supported by
univariate analyses: there was no statistically significant difference detected in
the proportion of cancer therapies across NICE decision categories.
Economic evidence and its impact on NICE decision making
Consistent with previously published analysis of NICE decision making (Devlin
and Parkin, 2004; Dakin et al., 2006), the ICER had a significant impact. An
increase in the ICER increased the odds of a restriction vs recommendation or
non-recommendation vs recommendation, and this effect was highly statistically
significant. The effect of the ICER was observed consistently throughout all of
the sensitivity analyses performed. Thus, in addition to the strength of the
clinical data, the incremental costs and benefits associated with the technology,
and the resulting ICER, play a significant role in decisions by NICE. This
interpretation of the multivariate model results is reinforced by a descriptive
assessment of the mean ICER reported for technologies that demonstrated
clinical superiority compared with those technologies that did not, suggesting
that the ICER is a product of the clinical value demonstrated (Figure 3). It is
recognised that ICERs represent a combination of inputs including clinical and
economic variables as well as disease and patient characteristics. According to
inputs used within an economic analysis, and the range of uncertainty accom-
panying them, this can lead to differing ICERs. It was on the basis of this
knowledge that, in addition to the base–case ICER, the analysis included data
on the range of base–case ICERs considered within the NICE review submitted
by stakeholders, and sensitivity analysis/uncertainty estimates around the
base–case ICER. However, these variablse were not found to have a significant
impact on NICE decision making, when adjusting for other factors.
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Figure 3. NICE decision-making: mean ICER stratified by demonstration of clinical
superiority in RCT (n5 90)
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The number of technologies appraised simultaneously affects NICE
decision making
The multivariate analyses also suggest that there are process factors, beyond
evidence considerations, which help to explain NICE decisions. An increase in
the number of technologies reviewed simultaneously within the same appraisal
increased the odds of a restriction relative to a recommendation. It was hypo-
thesised that this may reflect the fact that NICE assessment processes differ
according to the number of technologies under appraisal. However, when
the model specification was altered to include a variable capturing the use of
MTA or STA processes, the effect of this variable on NICE decisions was
not statistically significant. It was suggested that the increased odds of restriction
associated with higher number of technologies appraised simultaneously may
reflect an approach in which a ‘winner’ is picked among the technologies,
with the remainder recommended for restricted use or non-recommendation.
Descriptive analysis was performed of NICE decision outcome, stratified by the
number of technologies appraised (Figure 4): it suggests that the proportion
of restrictions increases with the number of technologies appraised, and
that non-recommendation appears to occur most frequently in appraisals with
fewer technologies appraised simultaneously. None of the previous multivariate
analyses of NICE decision making examined the role of process factors, and thus
comparison with earlier findings is not possible.
Year of appraisal affects NICE decision making
In terms of the socio-economic context of NICE decision making, it was
hypothesised that non-recommendations and restrictions are increasing over
time relative to recommendations. The analyses show that the year of appraisal
had a significant impact on NICE decisions – moving from 2004 to 2009
increased the odds of a restriction vs recommendation and non-recommendation
vs recommendation (Figure 5). The year of appraisal may reflect multiple socio-
economic factors, including the political climate, a change in key NICE staff,
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Figure 4. NICE decision-outcome stratified by number of technologies appraised (N5 118)
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a change in societal preferences or the overall economic context. It should be
noted that this analysis was performed before the implementation of changes in
NICE appraisal methods, including criteria for consideration in the appraisal of
rare diseases and cancer therapies. However, the analysis does cover the period
where other key changes took place in the appraisal process, including the
introduction of the Single-Technology Appraisal process as well as the 2008
update to the methods guide. By way of comparison, Dakin et al. (2006)
included this variable in their analyses and also found a statistically significant effect
of the time of appraisal on outcome: an increase in the time of appraisal (i.e. as the
appraisals came closer to the present), increased the odds of a non-recommenda-
tion. However, these authors did not find a statistically significant effect of appraisal
date on the odds of a restriction relative to a recommendation.
Limitations
Owing to limited resources, it was necessary to restrict the guidance included for
analysis and number of factors taking into account NICE decision making.
Although there are four types of guidance that NICE provides (NICE, 2008b),
this analysis focused on recommendations on pharmaceutical technologies. This
restriction on pharmaceutical technologies was done not only to increase the
homogeneity of the sample for analysis in terms of homogeneity of the tech-
nologies included, but also to increase homogeneity in the approach to decision
making, which can vary by type of guidance.
The variables included in this analysis represent factors for which indicators
could be defined and coded, and for which evidence could be collected retro-
spectively. Although not representing the complete set of factors taken into
Figure 5. NICE decisions between 2004–2009 (n5 118)
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account by NICE, they do represent the largest set of variables collected on NICE
decisions and represent a range of factors hypothesised to explain NICE decision
making. As the results show, the variables included in the analysis explain a pro-
portion of the variance of NICE decision making, highlighting that there is some
unexplained variance linked to variables that have not been captured in this
analysis, or to the fact that some influences on decisions are simply random.
The database constructed for these analyses, incorporating information on
appraisals performed by NICE from 2004 to 2009, was dependent on publicly
available information. Thus, it is possible that subtle concepts or rationales dis-
cussed by the appraisal committee orally were not captured in the documentation
of the appraisal. In addition, the dependence on public information meant that, in
the situation where the information available was incomplete, it was not possible to
ascertain whether this was because the information was never considered in the
appraisal or whether it was considered but not recorded in the documentation.
Incomplete observations were taken into account in the regression models by
creating dummy variables to examine whether the presence or absence of infor-
mation on that variable had any explanatory value. None of these dummy variables
appeared to have a significant effect on the odds of NICE decisions. A sensitivity
analysis was also performed in which incomplete observations were removed from
the sample for analysis. The results of this sensitivity analysis were similar to those
observed in the base–case analysis, suggesting that the factors identified in the
base–case model are robust to alternative model specifications.
There was heterogeneity in the means through which technologies were
restricted within NICE decisions. The notion of restriction within NICE deci-
sions ranged from major restrictions, including restriction for use within a
subset of the licensed indication, to minor restrictions such as the need for
monitoring along with the use of the technologies. The notion of major and
minor restrictions was suggested in research on NICE guidance by Raftery
(2006), in which various sub-types of restrictions were presented. O’Neill and
Devlin also highlighted the variation in the degree of restriction related to NICE
decision making (O’Neill and Devlin, 2010). It is a limitation of this analysis to
have such heterogeneity in the degree of restriction within a single category.
However, in its actual decision making, NICE has more than two coverage
options at its disposal and thus the use of a third coverage category within the
analysis reflected more closely real-life decision making. To test the impact of
using a binary outcome variable on the base–case model results, sensitivity
analysis was performed using a binary outcome variable, which confirmed the
role of the factors identified in the base–case analysis.
Conclusion
The objective of this analysis was to examine the factors that influence decisions
made by NICE to recommend, restrict or not recommend pharmaceutical
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technologies for use by the NHS in England and Wales. The analysis provided a
rich source of data from which to examine the role of each factor on NICE
decisions, and more importantly the contribution of each factor while adjusting
for the effect of confounding variables. The results suggest that the variability in
decisions observed can be explained by a combination of clinical, economic,
process and socio-economic factors. The analysis showed that the proportion of
restrictions and non-recommendations issued by NICE are increasing over time
relative to recommendations. The analysis also confirmed that the demonstra-
tion of clinical and economic value is central to NICE decisions. While the NICE
appraisal process was also shown to have an impact on decision making, the
anticipated effect of the use of STA or MTA processes was not observed; rather, an
effect was found for the number of technologies appraised simultaneously. New
factors not previously reported to have an effect on NICE decision making were
identified, including the effect of clinical superiority on NICE decision making,
the effect of the ICER on the likelihood of both restriction and recommendation
and that NICE decision making was sensitive to process variables as well as socio-
economic factors. The results confirm the value of a comprehensive and multi-
variate approach to understanding NICE decision making.
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